311 related articles for article (PubMed ID: 16237072)
1. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.
Cohen CJ; Zheng Z; Bray R; Zhao Y; Sherman LA; Rosenberg SA; Morgan RA
J Immunol; 2005 Nov; 175(9):5799-808. PubMed ID: 16237072
[TBL] [Abstract][Full Text] [Related]
2. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
Morgan RA; Dudley ME; Yu YY; Zheng Z; Robbins PF; Theoret MR; Wunderlich JR; Hughes MS; Restifo NP; Rosenberg SA
J Immunol; 2003 Sep; 171(6):3287-95. PubMed ID: 12960359
[TBL] [Abstract][Full Text] [Related]
3. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines.
Zhao Y; Zheng Z; Robbins PF; Khong HT; Rosenberg SA; Morgan RA
J Immunol; 2005 Apr; 174(7):4415-23. PubMed ID: 15778407
[TBL] [Abstract][Full Text] [Related]
4. Targeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells.
Liu X; Peralta EA; Ellenhorn JD; Diamond DJ
Cancer Res; 2000 Feb; 60(3):693-701. PubMed ID: 10676655
[TBL] [Abstract][Full Text] [Related]
5. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
[TBL] [Abstract][Full Text] [Related]
7. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
8. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
9. Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.
Zhao Y; Zheng Z; Khong HT; Rosenberg SA; Morgan RA
J Immunother; 2006; 29(4):398-406. PubMed ID: 16799335
[TBL] [Abstract][Full Text] [Related]
10. A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy.
Cho HI; Kim UH; Shin AR; Won JN; Lee HJ; Sohn HJ; Kim TG
Br J Cancer; 2018 Feb; 118(4):534-545. PubMed ID: 29360818
[TBL] [Abstract][Full Text] [Related]
11. TCR reconstitution in Jurkat reporter cells facilitates the identification of novel tumor antigens by cDNA expression cloning.
Aarnoudse CA; Krüse M; Konopitzky R; Brouwenstijn N; Schrier PI
Int J Cancer; 2002 May; 99(1):7-13. PubMed ID: 11948485
[TBL] [Abstract][Full Text] [Related]
12. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
Lin Y; Fujiki F; Katsuhara A; Oka Y; Tsuboi A; Aoyama N; Tanii S; Nakajima H; Tatsumi N; Morimoto S; Tamanaka T; Tachino S; Hosen N; Nishida S; Oji Y; Kumanogoh A; Sugiyama H
J Immunother; 2013 Apr; 36(3):159-70. PubMed ID: 23502763
[TBL] [Abstract][Full Text] [Related]
13. Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells.
Parkhurst MR; Joo J; Riley JP; Yu Z; Li Y; Robbins PF; Rosenberg SA
Clin Cancer Res; 2009 Jan; 15(1):169-80. PubMed ID: 19118044
[TBL] [Abstract][Full Text] [Related]
14. Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) alphabeta genes transduced to CD8+ T cells.
Hiasa A; Hirayama M; Nishikawa H; Kitano S; Nukaya I; Yu SS; Mineno J; Kato I; Shiku H
Gene Ther; 2008 May; 15(9):695-9. PubMed ID: 18288212
[TBL] [Abstract][Full Text] [Related]
15. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR.
Kuball J; Schmitz FW; Voss RH; Ferreira EA; Engel R; Guillaume P; Strand S; Romero P; Huber C; Sherman LA; Theobald M
Immunity; 2005 Jan; 22(1):117-29. PubMed ID: 15664164
[TBL] [Abstract][Full Text] [Related]
16. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
[TBL] [Abstract][Full Text] [Related]
17. Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells.
Meyer zum Büschenfelde C; Nicklisch N; Rose-John S; Peschel C; Bernhard H
J Immunol; 2000 Oct; 165(7):4133-40. PubMed ID: 11034426
[TBL] [Abstract][Full Text] [Related]
18. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
19. T-cell receptor gene therapy of established tumors in a murine melanoma model.
Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
[TBL] [Abstract][Full Text] [Related]
20. HLA class II restricted T-cell receptor gene transfer generates CD4+ T cells with helper activity as well as cytotoxic capacity.
van der Veken LT; Hoogeboom M; de Paus RA; Willemze R; Falkenburg JH; Heemskerk MH
Gene Ther; 2005 Dec; 12(23):1686-95. PubMed ID: 16034453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
